The mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions

Paola Malaguti, Sabrina Vari, Francesco Cognetti, Alessandra Fabi

Research output: Contribution to journalArticlepeer-review


Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3- kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogendependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalAnticancer Research
Issue number1
Publication statusPublished - Jan 2013


  • AKT
  • Breast cancer
  • Endocrine resistance
  • Everolimus
  • MTOR inhibitor
  • PI3K
  • Review
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'The mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions'. Together they form a unique fingerprint.

Cite this